Dejin Biology has completed a round A financing of tens of millions of yuan.

Recently, Zhejiang Dejin Biomedical Technology Co., Ltd. completed tens of millions of yuan in Series A financing, with Honghui Fund as the lead investor. The funds will be used for the clinical research, industrial base construction, and international layout of the company's restructured Type A Botulinum Toxin.